Track topics on Twitter Track topics that are important to you
Novartis has revealed that its drug Tafinlar (dabrafenib) has received approval from the FDA for use in combination with Mekinist (trametinib) in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express the BRAF V600E mutation.
Original Article: Novartis lung cancer combo receives FDA approvalNEXT ARTICLE
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...